C-Rad AB (LTS:0R44) Marketable Securities: kr0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R44 C-Rad AB LTS:0R44
83 GF Score
Price kr36.70
GF Value kr33.41
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is C-Rad AB Marketable Securities?

C-Rad AB LTS:0R44 -3.17% 83 Marketable Securities is kr0.0 Mil as of Jun. 2026. GuruFocus rates LTS:0R44 with a GF Score™ of 83/100 and a GF Value™ of kr33.41 (Fairly Valued). The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. C-Rad AB's Marketable Securities for the quarter that ended in Jun. 2026 was kr0.0 Mil.

C-Rad AB  (LTS:0R44) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

C-Rad AB Marketable Securities Related Terms

C-Rad AB Marketable Securities Historical Data

* Premium members only.

The historical data trend for C-Rad AB's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

C-Rad AB Marketable Securities Chart

C-Rad AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

C-Rad AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0R44
83GF Score
C-Rad AB LTS:0R44
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

C-Rad AB Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of kr0.0 Mil mean?
C-Rad AB (LTS:0R44) has a Marketable Securities of kr0.0 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on C-Rad AB and its competitors.
Is C-Rad AB's Marketable Securities too high?
C-Rad AB's current Marketable Securities is kr0.0 Mil. Overall, C-Rad AB has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's Marketable Securities compare to ABT and SYK?
C-Rad AB's Marketable Securities of kr0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on C-Rad AB and its competitors. C-Rad AB's current Marketable Securities is kr0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
Based on GuruFocus' analysis, C-Rad AB (LTS:0R44) is currently considered Fairly Valued. The stock's GF Value™ is kr33.41, compared to a current price of kr36.70 — trading 9.8% above its estimated fair value. The current Marketable Securities is kr0.0 Mil. C-Rad AB's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For C-Rad AB (LTS:0R44), the current Marketable Securities is kr0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is C-Rad AB (LTS:0R44) Overvalued in 2026?

Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued. The current stock price of kr36.70 is trading 9.8% above its estimated GF Value™ of kr33.41. GuruFocus considers C-Rad AB to be Fairly Valued.

Key valuation signals for LTS:0R44:

  • Marketable Securities: kr0.0 Mil
  • GF Value™: kr33.41 vs. price of kr36.70 (9.8% above fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the LTS:0R44 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

C-Rad AB Business Description

Other Exchanges CRAD B:Sweden24C:Germany
Address Sjukhusvagen 12K, Uppsala, SWE, 753 09
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
83GF Score

Get the complete analysis for LTS:0R44

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr36.70
Price
kr33.41
GF Value